Related Experiment Video
Updated: Jun 23, 2025
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic
Hang Liang1, Min Cui1, Jingyao Tu2
1Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract:
Osteosarcoma, a malignant bone tumor predominantly affecting children and adolescents, presents significant therapeutic challenges, particularly in metastatic or recurrent cases. Conventional surgical and chemotherapeutic approaches have achieved partial therapeutic efficacy; however, the prognosis for long-term survival remains bleak. Recent studies have highlighted the imperative for a comprehensive exploration of the osteosarcoma immune microenvironment, focusing on the integration of diverse immunotherapeutic strategies-including immune checkpoint inhibitors, tumor microenvironment modulators, cytokine therapies, tumor antigen-specific interventions, cancer vaccines, cellular therapies, and antibody-based treatments-that are directly pertinent to modulating this intricate microenvironment. By targeting tumor cells, modulating the tumor microenvironment, and activating host immune responses, these innovative approaches have demonstrated substantial potential in enhancing the effectiveness of osteosarcoma treatments. Although most of these novel strategies are still in research or clinical trial phases, they have already demonstrated significant potential for individuals with osteosarcoma, suggesting the possibility of developing new, more personalized and effective treatment options. This review aims to provide a comprehensive overview of the current advancements in osteosarcoma immunotherapy, emphasizing the significance of integrating various immunotherapeutic methods to optimize therapeutic outcomes. Additionally, it underscores the imperative for subsequent research to further investigate the intricate interactions between the tumor microenvironment and the immune system, aiming to devise more effective treatment strategies. The present review comprehensively addresses the landscape of osteosarcoma immunotherapy, delineating crucial scientific concerns and clinical challenges, thereby outlining potential research directions.
Insights
Osteosarcoma immunotherapy shows promise for treating this challenging bone cancer. Integrating diverse strategies like checkpoint inhibitors and vaccines may improve patient outcomes and survival rates.
Area of Science:
- Oncology
- Immunology
- Biomedical Research
Background:
- Osteosarcoma presents poor prognosis in metastatic or recurrent cases despite conventional treatments.
- The tumor immune microenvironment is crucial for understanding osteosarcoma progression and treatment resistance.
Purpose of the Study:
- To provide a comprehensive review of current advancements in osteosarcoma immunotherapy.
- To emphasize the integration of diverse immunotherapeutic strategies for optimizing treatment outcomes.
Main Methods:
- Review of recent studies and clinical trials on osteosarcoma immunotherapies.
- Analysis of various immunotherapeutic approaches including immune checkpoint inhibitors, cytokine therapies, and cellular therapies.
Main Results:
- Diverse immunotherapeutic strategies demonstrate potential in targeting tumor cells and modulating the immune microenvironment.
- Novel approaches like immune checkpoint inhibitors, cancer vaccines, and cellular therapies show promise for enhancing treatment efficacy.
Conclusions:
- Integrating various immunotherapeutic methods is crucial for improving osteosarcoma treatment outcomes.
- Further research into tumor microenvironment-immune system interactions is needed for developing more effective, personalized treatments.
Related Concept Videos
01:27Tumor Immunotherapy
02:17The Tumor Microenvironment
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...